{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.97","value":"69.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"}],"units":"Participants"}],"title":"Baseline (BL)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.70","value":"3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"title":"M3 Change from BL (CFB)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.63","value":"3.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"M6 CFB"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.72","value":"6.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"M9 CFB"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.55","value":"5.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"title":"M12 CFB"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.64","value":"6.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"title":"M18 CFB"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.33","value":"3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"title":"M24 CFB"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.81","value":"4.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"title":"M36 CFB"}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"}],"units":"Participants"}],"description":"Effect of tisagenlecleucel therapy on patient reported outcomes were reported using the EQ-VAS (EuroQol Visual Analogue Scale). The EQ-VAS is a 20 cm vertical, 0-100 numerical scale used alongside the EQ-5D questionnaire to measure a patient's self-rated health. It anchors \"best imaginable health\" (100) at the top and \"worst imaginable health\" (0) at the bottom, providing a quick, subjective, quantitative, and global assessment of health status on the day of survey","dispersionType":"Standard Deviation","groups":[{"description":"All participants who were enrolled in the study","id":"OG000","title":"CTL019: Physical Health Total Score"}],"paramType":"MEAN","populationDescription":"Efficacy analysis set (EAS): The number of participants in the EAS with an available value at each visit. EAS comprised of all participants who received tisagenlecleucel, and had measurable disease at baseline per IRC. Non-measurable disease at baseline is defined as absence of index lesion at baseline disease evaluation (i.e. no disease at baseline).","reportingStatus":"POSTED","timeFrame":"Baseline (BL), M3 change from baseline (CFB), M6 CFB, M9 CFB, M12 CFB, M18 CFB, M24 CFB, M36 CFB","title":"Summary Scores of PRO Measured by EQ-VAS Quality of Life Questionnaire Reported by Change From Baseline","type":"SECONDARY","unitOfMeasure":"scores on a scale"}